The Supervisory Board of 4SC AG (4SC, FSE Prime Standard: VSC) has appointed Kathleen Masch-Wiest as a new member of the Management Board. Kathleen Masch-Wiest is a lawyer and has already worked for 4SC AG in the past as a […]
Author: Firma 4SC
4SC AG: 4SC provides Q3 highlights and financial forecast
Posted on Posted in General
4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2022, as well as its current outlook. The full report is available for download on 4SC’s website (https://www.4sc.com/investors/investor-information/financial-reports/). Key highlights of […]
4SC AG: 4SC provides Q2 2022 and H1 2022 update
Posted on Posted in General
4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2022, presenting all material developments up to 30 June 2022 and the Company’s current outlook. The full communication is available for download on 4SC’s website (http://www.4sc.com/investors/investor-information/financial-reports/). Jason Loveridge, […]
4SC AG: 4SC – Resminostat and RESMAIN Study Update
Posted on Posted in Research / Development
4SC AG (4SC, FSE Prime Standard: VSC) today announced that the Data Safety Monitoring Board (DSMB), an independent committee of clinical and drug safety experts, recommends again continuation of the ongoing pivotal RESMAIN study without modification. The pivotal RESMAIN study, […]
4SC AG: 4SC provides Q1 2022 update
Posted on Posted in General
4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2022, presenting all material developments up to 31 March 2022 and the Company’s current outlook. The full communication is available for download on 4SC’s website (http://www.4sc.com/investors/investor-information/financial-reports/). Jason Loveridge, […]
4SC AG provides results for financial year 2021 and outlook for 2022
Posted on Posted in General
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 2021, presenting all material reporting period developments and provides an outlook for 2022. The full report is available at 4SC’s website […]
4SC AG: 4SC AG – Discontinuation Domatinostat Program
Posted on Posted in Research / Development
The Management Board and Supervisory Board of 4SC AG (FSE Prime Standard: VSC) today decided that as a result of a review of more recent clinical data 4SC discontinues the development program for domatinostat, an orally administered small molecule class […]
More than 80% of events now reached for unblinding of RESMAIN
Posted on Posted in Research / Development
4SC AG (4SC, FSE Prime Standard: VSC) today announced that more than 80% of the events required to unblind the pivotal RESMAIN study of resminostat in cutaneous T-cell lymphoma (CTCL) had been observed. The occurrence of a well-defined event such […]
4SC AG: 4SC – Recruitment target of 190 patients now reached in RESMAIN
Posted on Posted in General
4SC AG (4SC, FSE Prime Standard: VSC) today announced that the 190th patient was enrolled into the pivotal RESMAIN study of resminostat in cutaneous T-cell lymphoma (CTCL). Patients with advanced stage Mycosis fungoides or Sézary syndrome have been recruited in […]
4SC AG – Domatinostat Program Update
Posted on Posted in Research / Development
4SC AG (4SC, FSE Prime Standard: VSC) today announced the results of a scheduled review of 4SC’s program for the clinical development of domatinostat, an orally administered small molecule class I selective HDAC inhibitor. As a result of this review […]